| Nikolaos Chandolias, MD | |
|
8480 Limekiln Pike Apt 203, Wyncote, PA 19095-2804 | |
| (518) 530-2690 | |
| (215) 456-6716 |
| Full Name | Nikolaos Chandolias |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 22 Years |
| Location | 8480 Limekiln Pike Apt 203, Wyncote, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164622031 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | LP01122 (Rhode Island) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Albert Einstein Medical Center | Philadelphia, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Einstein Practice Plan Inc | 2769395896 | 591 |
News Archive
In this post in the Center for Strategic & International Studies' (CSIS) "Smart Global Health" blog, Rhonda Zygocki, executive vice president of policy and planning at Chevron, responds to questions about Chevron's presence at the XIX International AIDS Conference (AIDS 2012) in Washington, D.C., last week, writing that such questions "give me an opportunity to talk about the critical role everyone plays in the global fight against this epidemic, including Chevron, as well as the ways collaborative partnerships will lead to the elimination of AIDS."
Research to be presented at the upcoming annual meeting of the Society for the Study of Ingestive Behavior (SSIB), the foremost society for research into all aspects of eating and drinking behavior, suggests that ghrelin, a naturally occurring gut hormone, increases our willingness to pay for food, while simultaneously decreasing our willingness to pay for non-food items.
Scientists at Harvard University have used light and genetic trickery to trace out neurons' ability to excite or inhibit one another, literally shedding new light on the question of how neurons interact with one another in live animals.
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products, today announced that will host a conference call at 4:30 pm ET on Thursday, October 29, 2009 to discuss the Company's financial results for the three-month period ended September 30, 2009 – the first quarter of ImmunoGen's 2010 fiscal year.
This week the African nation of Malawi became one of the first of the planned three to launch a pilot trial for a novel vaccine against malaria. The news and the efforts were lauded by the World Health Organization (WHO).
› Verified 7 days ago
| Entity Name | Einstein Practice Plan Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760434468 PECOS PAC ID: 2769395896 Enrollment ID: O20040219000728 |
News Archive
In this post in the Center for Strategic & International Studies' (CSIS) "Smart Global Health" blog, Rhonda Zygocki, executive vice president of policy and planning at Chevron, responds to questions about Chevron's presence at the XIX International AIDS Conference (AIDS 2012) in Washington, D.C., last week, writing that such questions "give me an opportunity to talk about the critical role everyone plays in the global fight against this epidemic, including Chevron, as well as the ways collaborative partnerships will lead to the elimination of AIDS."
Research to be presented at the upcoming annual meeting of the Society for the Study of Ingestive Behavior (SSIB), the foremost society for research into all aspects of eating and drinking behavior, suggests that ghrelin, a naturally occurring gut hormone, increases our willingness to pay for food, while simultaneously decreasing our willingness to pay for non-food items.
Scientists at Harvard University have used light and genetic trickery to trace out neurons' ability to excite or inhibit one another, literally shedding new light on the question of how neurons interact with one another in live animals.
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products, today announced that will host a conference call at 4:30 pm ET on Thursday, October 29, 2009 to discuss the Company's financial results for the three-month period ended September 30, 2009 – the first quarter of ImmunoGen's 2010 fiscal year.
This week the African nation of Malawi became one of the first of the planned three to launch a pilot trial for a novel vaccine against malaria. The news and the efforts were lauded by the World Health Organization (WHO).
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nikolaos Chandolias, MD 8480 Limekiln Pike, Apt 203, Wyncote, PA 19095 Ph: (518) 530-2690 | Nikolaos Chandolias, MD 8480 Limekiln Pike Apt 203, Wyncote, PA 19095-2804 Ph: (518) 530-2690 |
News Archive
In this post in the Center for Strategic & International Studies' (CSIS) "Smart Global Health" blog, Rhonda Zygocki, executive vice president of policy and planning at Chevron, responds to questions about Chevron's presence at the XIX International AIDS Conference (AIDS 2012) in Washington, D.C., last week, writing that such questions "give me an opportunity to talk about the critical role everyone plays in the global fight against this epidemic, including Chevron, as well as the ways collaborative partnerships will lead to the elimination of AIDS."
Research to be presented at the upcoming annual meeting of the Society for the Study of Ingestive Behavior (SSIB), the foremost society for research into all aspects of eating and drinking behavior, suggests that ghrelin, a naturally occurring gut hormone, increases our willingness to pay for food, while simultaneously decreasing our willingness to pay for non-food items.
Scientists at Harvard University have used light and genetic trickery to trace out neurons' ability to excite or inhibit one another, literally shedding new light on the question of how neurons interact with one another in live animals.
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products, today announced that will host a conference call at 4:30 pm ET on Thursday, October 29, 2009 to discuss the Company's financial results for the three-month period ended September 30, 2009 – the first quarter of ImmunoGen's 2010 fiscal year.
This week the African nation of Malawi became one of the first of the planned three to launch a pilot trial for a novel vaccine against malaria. The news and the efforts were lauded by the World Health Organization (WHO).
› Verified 7 days ago